Advances in the treatment of respiratory allergic diseases by montelukast
10.16571/j.cnki.1008-8199.2019.09.018
- VernacularTitle: 孟鲁司特治疗呼吸道变应性疾病的研究进展
- Author:
Ruo-yu CHEN
1
;
Bo-han NING
1
;
Hua PENG
1
Author Information
1. Department of Otorhinolaryngology, General Hospital of Southern Theater Command, PLA, Guangzhou 510010,Guangdong,China
- Publication Type:Journal Article
- Keywords:
montelukast;
allergic rhinitis;
bronchial asthma;
cough variant asthma;
eosinophilic bronchitis
- From:
Journal of Medical Postgraduates
2019;32(9):988-993
- CountryChina
- Language:Chinese
-
Abstract:
Airway allergic diseases are characterized by chronic inflammatory responses in airways. Leukotriene antagonists have been recently recommended as the first-line medication for respiratory allergic diseases, along with nasal glucocorticoids and antihistamines, due to their prominent efficacy and safety in allergic inflammation. This review summarized the clinical application of Montelukast, the representative drug of leukotriene antagonists, to treat allergic rhinitis, bronchial asthma, cough variant asthma, eosinophilia bronchitis and other diseases, in order to further explore the advantages and prospect of Montelukast in the application of airway allergic inflammation.
